Pharmaceutical Price Regulation Scheme Archives -

Companies who are thinking about seeking funding via England’s new Innovative Medicines Fund (IMF) need to think through

Trying to get clarity on CDF and VPAS and implications for the IMF

https://pharmaphorum.com/views-and-analysis/trying-to-get-clarity-on-cdf-and-vpas-and-implications-for-the-imf/

Should there be a different review of NICE as part of a successor PPRS?

NICE numbers: trends in recommendations should prompt a review of NICE

https://pharmaphorum.com/views-and-analysis/nice-numbers-trends-recommendations/

Has the PPRS delivered on the aim to support the government’s growth and innovation agenda?

Could the PPRS support a changing growth and innovation agenda?

https://pharmaphorum.com/views-and-analysis/pprs-support-changing-growth-innovation-agenda/

Has the PPRS delivered on the aim of reducing bureaucracy and duplication?

Bureaucracy and duplication: the reality of the PPRS

https://pharmaphorum.com/views-and-analysis/bureaucracy-duplication-pprs/

Keeping the UK branded medicines bill within affordable limits – has PPRS delivered?

Improved access? The reality of the PPRS

https://pharmaphorum.com/views-and-analysis/improved-access-reality-pprs/

Has the UK PPRS scheme met its five objectives?

Unstable and unpredictable? The reality of the PPRS

https://pharmaphorum.com/views-and-analysis/pprs-pharmaceutical-price-regulation-scheme/

Pharmaceutical Price Regulation Scheme